BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China
BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China
简介-深圳芯屏生物科学公司宣布NMPA新药在中国获得Bilessglu批准
Oct 19 (Reuters) - Shenzhen Chipscreen Biosciences Co Ltd
路透10月19日电-深圳晶屏生物科学有限公司
688321.SS :
688321.SS:
* SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD - ANNOUNCES NMPA NEW DRUG APPROVAL OF BILESSGLU (CHIGLITAZAR SODIUM TABLETS) FOR ( TYPE 2 DIABETES) IN CHINA
*深圳CHIPSCREEN生物科学有限公司-宣布NMPA批准治疗2型糖尿病的BILESSGLU(CHIGLITAZAR钠片)在中国获得新药批准
Source text for Eikon: ID:nPn2nXW6va Further company coverage: 688321.SS
Eikon的源文本:ID:nPn2nXW6va进一步的公司报道:688321.SS
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com;)